COSCIENS Biopharma ( (TSE:CSCI) ) has issued an update.
COSCIENS Biopharma Inc. has announced the successful completion of its Phase 1 clinical trial for its avenanthramides product, paving the way for the initiation of a Phase 2a clinical efficacy trial. The Phase 1 trial, part of the AvenActive study, demonstrated a favorable safety profile with no significant adverse events, leading to the recommendation to proceed with Phase 2a. This next phase will assess the potential efficacy of avenanthramides in patients with mild to moderate inflammation, marking a significant step in the company’s efforts to position its product as a viable anti-inflammatory treatment.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products. The company focuses on creating products with potential applications in managing inflammation-related conditions.
YTD Price Performance: -1.47%
Average Trading Volume: 7,541
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.53M
For an in-depth examination of CSCI stock, go to TipRanks’ Stock Analysis page.